mpany
based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has
a robust clinical development pipeline of product candidates. Millennium
research, development and commercialization activities are focused in
oncology. Additional information about Millennium is available through its
website,
http://www.millennium.com.
Editor's Note: This press release is also available under the Media
section of the Company's website at: http://www.millennium.com
Media Contact:
Manisha Pai
(617)551-7877
manisha.pai@mpi.com
'/>"/>SOURCE Millennium Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 Related biology technology :1.
Mark C. Mirken Named New CEO and Chairman of the Board of Millennium Biotechnologies, Inc.2.
Joseph B. Bolen, Ph.D. from Millennium to Conference Chair Cancer Sessions at IBCs Drug Discovery & Development of Innovative Therapeutics Conference3.
Millennium Biotechnologies Announces an Increased Annualized Purchase Commitment Totaling $5.8M from Provider Services, Inc.4.
Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period5.
Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion6.
Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales7.
Millennium Announces $200,000 Purchase Order From Greek Distributor8.
Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals9.
Millennium Over-Delivers on 2007 Goals and Financial Guidance10.
Millennium Biotechnologies Group Reports 40% Sales Increase for Resurgex Product Line in Greek Market11.
Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results